Mizuho Reiterates Buy Rating for Corbus Pharmaceuticals
Mizuho maintains its positive outlook on Corbus Pharmaceuticals, setting a $34 price target, a 312.12% upside from the current price.
Key Points
- Mizuho reiterated its buy rating for Corbus Pharmaceuticals on June 23, 2026, with a price target of $34.
- Mizuho's $34 price target implies 312.12% upside from Corbus Pharmaceuticals Holdings, Inc.'s ($CRBP) current $8.25 share price.
- Shares of CRBP traded at $8.31 on Tuesday, with a market cap of approximately $154 million.
- Major insiders include Chief Business Officer Nishant Saxena, who acquired shares in early June.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 23, 2026, Mizuho reiterated its buy rating for Corbus Pharmaceuticals Holdings, Inc. (NasdaqCM: CRBP), maintaining a price target of $34. Analyst Graig Suvannavejh continues to see potential in the biotechnology firm.
Mizuho vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in Corbus Pharmaceuticals
Several funds have shown varied interest in Corbus Pharmaceuticals. Cormorant Asset Management, LP held steady with 2,344,971 shares valued at about $22 million. Orbimed Advisors LLC increased its stake by 140,000 shares, bringing its total to 1,737,287 shares worth approximately $16.3 million, marking an 8.8% increase. Vanguard Capital Management LLC opened a new position with 734,106 shares valued at around $6.9 million. Meanwhile, Citadel Advisors LLC reduced its holdings by 116,133 shares, now holding 727,060 shares valued at about $6.8 million, a 13.8% decrease.
Corbus Pharmaceuticals Holdings, Inc. Stock Down 24.4%
Shares of NasdaqCM:CRBP traded near $8.31 on Tuesday. Corbus Pharmaceuticals has a market cap of approximately $154 million and a beta of 2.59, indicating higher volatility. The stock's 52-week range is between $6.72 and $20.56, with a 50-day moving average of $9.54 and a 200-day moving average of $10.23. The company, which is not currently profitable, has no meaningful P/E ratio.
$CRBP price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Corbus Pharmaceuticals Holdings, Inc.
Several insiders have been active in trading Corbus Pharmaceuticals stock. On June 10, 2026, Jenkins John Kenneth, Winston Kung, and Anne Altmeyer sold shares at an average price of $7.91 as part of planned transactions. Chief Business Officer Nishant Saxena made multiple purchases in early June, acquiring 9,000 shares at $7.58 on June 3, 4,500 shares at $7.33 on June 2, and 58,300 shares on May 21.
Analysts Set New Price Targets
Mizuho maintained its buy rating for Corbus Pharmaceuticals with a $34 target on June 23, 2026. Oppenheimer also maintained its buy rating on June 17, with a higher target of $52. On May 26, HC Wainwright & Co. reiterated a buy rating with a $40 target. The consensus among analysts is a strong buy, with an average price target of $36.30 based on 10 opinions.
About Corbus Pharmaceuticals
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapeutics for cancer and obesity. With its headquarters in Norwood, Massachusetts, the company is led by CEO Dr. Yuval Cohen. Corbus is working on CRB-701, an antibody drug conjugate targeting Nectin-4 in cancer cells, and CRB-913 for obesity treatment. Founded in 2009, Corbus employs 36 people.
Bottom Line
Mizuho's reiterated buy rating and $34 price target suggest confidence in Corbus Pharmaceuticals' future prospects. Investors track these analyst opinions closely, but it's important to remember that these ratings are backward-looking. Corbus' focus on innovative treatments in cancer and obesity makes it a company to watch in the healthcare sector.
Get Corbus Pharmaceuticals Holdings, Inc. alerts
New 13F filings, insider trades, and analyst moves on $CRBP, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.